

CORPET INSTRUCTION LEAFLET

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing Firm - Free Sale Certificate:

Mycology Research Laboratories Ltd.
Windsor House
9-15 Adelaide Street
Luton, Bedfordshire LU1 5BJ
United Kingdom
Tel:+44-1582-485-209
Fax:+44-1582-485-209

Manufacturer:

NovoLumen
Tasveld 8
3417 XS Montfoort, Nederland

2. NAME OF THE PRODUCT

CORPET-500 mg tablets of fungus *Coriolus versicolor* biomass (Strain CV-OH1).

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Coriolus versicolor tablets contains both mycelium and primordia (young fruit body) cultivated into a biomass that is grown on a sterilised (autoclaved) substrate.

This cultivation process ensures the powder is free from contamination by other fungi and that pesticides and heavy metals are absent.

The cultivation system is proprietary, allowing for standardised production of *Coriolus versicolor*.

The *Coriolus versicolor* is processed under the same rigorously controlled conditions that are applied to the manufacture of a conventional pharmaceutical. This ensures that each tablet contains 500 mg of the standardised *Coriolus* product.

Corpet is comprised of 500 mg tablets of *Coriolus versicolor* biomass powder with strain number CV-OH1.

The proprietary cultivation process for CV-OH1 (Corpet) is conducted in California. The process involves the use of the "mother culture" of strain CV-OH1 that has been developed and maintained in isolation and this is used to produce the spawn.

The cultivation process allows for the harvesting of the mycelium and the young fruiting body (primordia). This cultivation technique produces a *Coriolus versicolor* that is sterile and contains no pesticides, heavy metals, is free from foreign matter and is totally reproducible. The material is shipped from California to Holland where it is manufactured into 500 mg tablets with the addition of cellulose, silica, a granulating agent and a tablet press lubricant.

4. INDICATIONS

- 4.1. Support the immune system in small animals undergoing surgery.
- 4.2. Support the immune system in small animals with viruses (FELV in cats).
- 4.3. Support the immune system in small animals exposed to Leishmaniose Visceral.
- 4.4. Support the immune system in small animals as they age.

(Indications 4.1 to 4.4: Supplementation Schedule I)

4.5. Support the immune system in small animals with advanced oncological conditions as a palliative supplement. **See *Supplementation Schedule II***.

5. CONTRAINDICATIONS

Should not be given to animals undergoing a bone marrow transplantation where the immune system has risk of rejecting the new organ.

6. ADVERSE REACTIONS

Diarrhea for 48 hours, if advances longer than 48 hours discontinue supplementation.

7. TARGET SPECIES

Small animals (cats and dogs).

8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION

Small Animal Supplementation Schedules (See Indications section)

Supplementation Schedule I

Cats / Dogs Weight	Day 1 to 60 Loading Phase	Day 60+ Maintenance Phase
Less than 10 kilos	2 tablets / day	1 tablet / day
Between 10 to 30 kilos	4 tablets / day	2 tablets /day
Over 30 kilos	6 tablets / day	3 tablets / day

Supplementation Schedule II

Cats / Dogs Weight	Day 1 to 60 Loading Phase	Day 60+ Maintenance Phase
Less than 10 kilos	2 tablets / day	2 tablets / day
Between 10 to 30 kilos	4 tablets / day	4 tablets / day
Over 30 kilos	6 tablets / day	6 tablets / day

9. ADVICE ON CORRECT ADMINISTRATION

Crush tablets and mix with meals.

10. WITHDRAWAL PERIOD

None.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the reach and sight of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use after the expiry date stated on the bottom of bottle.

12. SPECIAL WARNING(S)

None.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

None.